Mesenchymal stem cell-based therapy for ischemic stroke

Johnathon D. Anderson1,11*, Missy T. Pham1, Zelenia Contreras1, Madeline Hoon1, Kyle D. Fink1, Henrik J. Johansson2, Julien Rossignol3, Gary L. Dunbar1, Megan Showalter4, Oliver Fiehn1,5, Charles S. Bramlett1, Renee L. Bardini1, Gerhard Bauer1, Brian Fury1, Kyle J. Hendrix1, Frederic Chedin6, Samir EL-Andaloussi7,8,9, Billianna Hwang10, Michael S. Mulligan10, Janne Lehtiö2 and Jan A. Nolta1

Abstract

Ischemic stroke represents a major, worldwide health burden with increasing incidence. Patients affected by ischemic strokes currently have few clinically approved treatment options available. Most currently approved treatments for ischemic stroke have narrow therapeutic windows, severely limiting the number of patients able to be treated. Mesenchymal stem cells represent a promising novel treatment for ischemic stroke. Numerous studies have demonstrated that mesenchymal stem cells functionally improve outcomes in rodent models of ischemic stroke. Recent studies have also shown that exosomes secreted by mesenchymal stem cells mediate much of this effect. In the present review, we summarize the current literature on the use of mesenchymal stem cells to treat ischemic stroke. Further studies investigating the mechanisms underlying mesenchymal stem cells tissue healing effects are warranted and would be of benefit to the field.

Keywords: Mesenchymal stem cells, Exosomes, Ischemic stroke

Background

Stroke is the second leading cause of death and its prevalence is increasing [1]. Stroke can be classified into two types, ischemic and hemorrhagic, of which the former comprises up to 80 % of all cases [2]. Ischemic stroke occurs when blood flow decreases in the cerebrum as a result of an obstruction, such as an embolism or thrombus [3]. Currently, the only approved treatment for ischemic stroke is tissue plasminogen activator (tPA) [4]. However, tPA has a narrow therapeutic window of only 4.5 h from the onset of symptom [5]. Consequently, most stroke patients don’t qualify for this treatment and would greatly benefit from the development of novel treatments that have an expanded therapeutic window [5].

Adult stem cell-based therapies, such as mesenchymal stem cells (MSCs) have emerged as a promising approach for the treatment of ischemic stroke [6]. MSCs are good candidates for the treatment of stroke as they are easily obtained and have a strong safety profile [7]. MSCs have demonstrated beneficial effects in improving functional outcome through mechanisms implicated in brain plasticity such as neurogenesis, axonal sprouting, and angiogenesis [6].

In this review, we summarize the current literature on MSCs and their potential use as a therapeutic in cases of ischemic stroke.

Review

Phenotype of MSCs

MSCs are adult multipotent cells which can differentiate into osteo, adipo and chondro lineages [8]. MSCs can be isolated from bone marrow, umbilical cord and adipose tissue [9]. MSCs express the mesenchymal markers CD105, CD90, and CD73 but express few HLA class I and no HLA class II molecules, allowing them to evade allogeneic immune response, making them well suited for allogeneic use [10].

MSCs mediate tissue healing in damaged organs including ischemic stroke, myocardial infarction and liver injury [11]. MSCs activate endogenous cellular repair...
programs by releasing various secretory proteins such as fibroblast growth factor, epidermal growth factor, insulin-like growth factor and monocyte chemoattractant protein-1 [12]. MSCs have also been shown to induce angiogenesis and vascular remodeling via factors such as vascular endothelial growth factor, angiopoietins and hepatocyte growth factor [13]. Additionally, MSCs secrete IL-10, IL-6 and nitric oxide which induce a localized anti-inflammatory state, thereby facilitating the healing of damaged tissue [14].

Several studies demonstrate that small celluarily secreted vesicles called exosomes mediate much of MSCs’ tissue healing capabilities [15–28]. MSC derived exosomes are internalized by target cells and transfer proteins, RNA, lipids and metabolites [29]. Our recent study determined that ex-vivo expanded MSCs substantially increase their secretion of exosomes upon exposure to in vivo-like conditions and that these exosomes contain a diverse profile of prosurvival and angiogenic proteins [30].

Studies have demonstrated that MSCs are immunomodulatory and are capable of reducing pathogenic inflammatory [31]. MSCs can exert profound immunosuppression both in vitro and in vivo by inhibiting the proliferation of T-cells, natural killer cells, and dendritic cells [32]. MSCs have also been reported to induce proliferation of immune suppressive Treg cells, at least in part by inducing the differentiation of monocytes towards resident M2 macrophages [33].

**MSCs in the treatment of ischemic stroke**

Ischemic stroke is a major cause of death and disability in the aged population [34]. During cerebral infarction, transplanted MSCs migrate to areas of damage and mediate tissue healing [35]. MSCs induce angiogenesis, neurogenesis and neurite outgrowth in the surrounding endogenous tissue through the secretion of neuroprotective factors [6, 24, 36]. MSCs have generally been injected intracranially or intravascularly [6]. Some evidence suggests that intravascular MSC administration after stroke may be a viable alternative to intracranial transplantation, but more work in this area is needed before definitive statements can be made [37]. However, intravascular delivery may be better for larger lesions as it could lead to a wider distribution of transplanted cells around lesions than intracranial delivery, but also potentially dilutes out the therapeutic effect across a larger volume.

Numerous studies have reported favorable outcomes in immune-competent ischemic stroke rodent models upon treatment with MSCs (Table 1) [38–57]. Many, but not all, of these studies reported MSCs reduced infarct size and induced functional recovery as reported by lessening of motor deficits or special learning as measured by the radial maze test [38–57]. Many of these studies report a lowering of deficits as assessed by the composite modified neurological severity score (mNSS), while others demonstrated reduced inflammation and apoptosis, as well as increased neurite outgrowth and plasticity [38–57]. Interestingly, recent studies have also determined that exosomes secreted by MSCs are capable of inducing functional recovery in models of ischemic stroke [24, 41, 47, 55, 58].

**MSCs, their mechanism of action and safety profile**

While not fully understood, postulated mechanisms of actions proposed to account for therapeutic effects of MSCs include cell replacement, growth factor secretion, and biobridge formation [59]. Stroke therapeutics have been categorized as ‘neuroprotective’ for the acute phase or ‘neuroregenerative’ for the subacute and chronic stages of stroke [59]. The acute treatment in stroke is relegated to tPA and other drugs that are designed to maintain structure and functionality of the blood vessels. The subacute (several hours to a few days) and chronic (several days, to weeks, months, and even years) phases are the targeted window for MSC transplant therapy. For the subacute phase, MSC transplantation has been shown to abrogate the early secondary cell death responses associated with stroke, such as dampening the oxidative stress, inflammation, mitochondrial impairment, and apoptosis [60]. On the other hand, MSC treatment in the chronic phase has been demonstrated to trigger brain remodeling via angiogenesis, vasculogenesis, neurogenesis, and synaptogenesis [61]. The minimally invasive intravenous or intra-arterial delivery of stem cells has been the preferred choice for the subacute phase due to an already injured brain produced by the primary ischemic insult, combined with chemottractants that can guide migration of MSCs from the periphery to the brain. The direct intracerebral implantation of stem cells to the peri-infarct region is utilized for the chronic phase with the stroke brain more tolerant of an invasive treatment procedure, but also because of tapered levels of chemottractants [62]. Direct transplantation was initially examined in chronic stroke patients using neural progenitor cells (NT2N) [63] and in recent years using Notch-induced bone marrow cells (SB-623) [64], with subsequent clinical trials employing intravenous and intra-arterial administration of MSCs in subacute stroke patients [65, 66].

Cell therapy for stroke has tested several types of transplantable cells in the laboratory, with a few reaching clinical trials, such as fetal cells, NT2N cells, CTX0E3, embryonic stem cells, neural stem/progenitor cells, umbilical cord blood, amnion, adipose, and induced pluripotent stem cells [67–72]. Compared to these other stem cells, MSCs have established a solid safety profile in other disease indications, providing the basis for on-going clinical trials to explore MSCs and their cell subpopulations.
As noted above, MSCs have been transplanted intracerebrally and peripherally [73, 75–78], with encouraging pilot studies reporting safety, but efficacy remains to be fully assessed [74].

**Translational challenges of MSC therapy for stroke**

Recent clinical trials on transplantation of MSCs have shown their safety in stroke [75, 79–81]. In addition to the small number of patients enrolled in these clinical trials, the translation of laboratory protocols for clinical transplant regimens has been marred with major discrepancies including the lack of well-defined release criteria of the donor cells, varying timing, cell dose and route of transplant intervention, altogether deviating from the established preclinical readouts. In particular, many of the clinical trials were not performed along the guidelines of Stem cell Therapeutics as an Emerging Paradigm for Stroke or STEPS lab-to-clinic translational guidelines [82]. The recommended translational research approach is to use at least two models of stroke using small animals (rodents). Any unanswered issues related to safety and efficacy, as well as insights into mechanisms of action, need to be pursued using a large animal model (non-human primates). A rigorous preclinical testing, as recommended by the STEPS guidelines will increase the likelihood of success of future clinical trials of MSC transplant therapy for stroke.

**Conclusions**

Although numerous studies have demonstrated that MSCs facilitate tissue healing and functional recovery in rodent models of ischemic stroke, several outstanding issues in the field warrant further investigation. The underlying mechanisms by which MSCs respond to their environmental niche upon injection healing is poorly understood [83]. MSCs generally have a relatively short half-life which limits their ability to heal damaged tissue [84]. A major goal for the field should be to develop

| Table 1 | Studies demonstrating the efficacy of MSC-based therapies for the treatment of ischemic stroke in rodent models |
|---------|---------------------------------------------------------------------------------------------------------------|
| Author  | Type of Cells                                     | Stroke model | Delivery | Effect | Histology                  | Outcomes                        |
| Brenneman, M | BM-MSC (Rat)                                 | CCAO/MCAO  | 24 h     | Y      | TCC, TUNEL, DAPI, fluorescein | Decreased infarct                |
| Chen J   | BM-MSC (Rat)                                   | MCAO       | 24 h     | Y      | H&E, Y chr, TUNEL           | Increased rotarod, adhesive     |
| Chen, JR | BM-MSCs (Rat)                                  | MCAO       | Immediate | Y      | Nissel, GFAP, GalC, MAP2, Tuj1, BrdU | Decreased infarct               |
| Doepnner TR | BM MSC & Exosomes (Human)                  | MCAO       | Days 1,3,5 | Y      | cresyl violet, Neun, BrdU   | Increased rotarod, tightrope    |
| Goldmacher, GV | BM-MSCs (rat)                  | MCAO       | Immediate | Y      | TTC, HNA, GFAP, CD11        | Decreased mNSS                  |
| Fernandez, M | Adipose-MSC (Human, Rat)          | Permanent MCAO | 30 mins | Y      | H&E, TUNEL, GFAP, VEGF, SYP, DAPI | Decreased cell death            |
| Honma, T  | MCS-Telomerase (Human)                      | MCAO       | 12 h     | Y      | H&E, TTC. Beta-gal, NeuN, GFAP | Decreased infarct, inflammation |
| Koh, SH   | UC-MSC (Human)                               | MCAO       | 2 weeks  | Y      | Neun, SNE, GFAP, nestin     | Decreased mNSS                  |
| Li Y      | BM-MSC (Human)                               | MCAO       | 1 day    | Y      | H&E, NeuN, MAP-2, GFAP, vWF, TUNEL | Decreased mNSS                  |
| Lim, JY   | UC-MSC (Human)                               | MCAO       | 72 h     | Y      | TTC, NeuN, GFAP, DAPI, TUNEL | Decreased infarct               |
| Liu, N    | BM-MSC-SVV (Rat)                             | MCAO       | 26 h     | Y      | TTC, NeuN, GFP              | Decreased infarct               |
| Nomura, T | BM-MSC-BDNF (Human)                         | MCAO       | 6 h      | Y      | TCC, Beta-gal, NeuN, GFAP   | Decreased infarct               |
| Quittet MS | BM-MSC-PAM-VEGF (Rat)                        | MCAO       | 24 h     | N      | BrdU, NeuN, GFAP, CASP2, DCX, K67 | No Difference                  |
| Wei, L    | BM-MSC (Rat)                                 | MCAO       | 24 h     | Y      | BrdU, NeuN, MAP2, GFAP, Tuj1, Iba-1 | Increased rotarod               |
| Yamauchi T | BM-MSC (Human)                              | Permanent MCAO | 7 days  | Y      | Tuj-1, NeuN, GFAP           | Increased rotarod, radial maze  |
| Yang C    | BM-MSC-HIF1a (Rat)                           | MCAO       | 6 h      | Y      | TTC, CD105                  | Decreased infarct, mNSS         |
| Toyoshima, A | BM-MSC (Rat)                              | MCAO       | 24 h     | Y      | DAPI, Q-Tracker, TCC       | Decreased infarct, mNSS         |
| Xin, H    | BM-MSC (Rat)                                 | MCAO       | 24 h     | Y      | BDA-DAB, NF-200, SYP       | Decreased adhesive, foot-fault  |
| Xin, H    | BM-MSC (Mouse)                               | MCAO       | 24 h     | Y      | Nissl, Luxol, SYP, Apo-TAG  | Increased neurites, plasticity  |
| Lowrance, SA | BM-MSC (Rat)                              | MCAO       | 7 days   | Y      | Hoescht, GFAP               | Decreased SORT                  |
strategies augment the half-life of MSCs upon injection into affected tissue [10]. Hypoxic preconditioning has garnered some beneficial effects in this regard, but more investigation is needed [8].

The molecular mechanisms underlying MSCs therapeutic effects are also poorly understood at present. More detailed mechanistic studies of MSCs’ therapeutics effects are warranted and sorely needed. These endeavors would be greatly rewarding in a field where more and more labs are attempting to genetically engineer MSCs with enhanced therapeutic profiles [9]. In addition, MSC secreted exosomes is a field that merits continued exploration, as the discovery of these vesicles has given us the profound insight that the sheer variety of communication signals MSC use to mediate tissue is likely orders of magnitudes higher than previously expected. Indeed, the field has only recently begun to investigate the protein, RNA, lipid and metabolite cargo exosomes transport from MSCs to neighboring cells.

Abbreviations
mNSS: Modified neurological severity score; MSCs: Mesenchymal stem cells; tPA: Tissue plasminogen activator

Acknowledgement
The authors acknowledge the funding sources NIH Translational R01GM099688, NSF GRFP 2011116000, NIH T32-GM087979, NSF GROW 201111600, NIH T32-HL086350, NIH U2DK097154.

Funding
The authors are supported by NIH Translational R01GM099688, NSF GRFP 2011116000, NIH T32-GM087979, NSF GROW 201111600, NIH T32-HL086350, NIH U2DK097154.

Availability of data and materials
This paper is a review article. Referred literature in this paper has been listed in the references part. The datasets supporting the conclusions of this article are available online by searching the PubMed. Some original points in this article come from the laboratory and clinical practice in our research centers and the authors’ experiences.

Authors’ contributions
JDA: Conception and design, collection and/or assembly of data and interpretation, manuscript writing, final approval of manuscript; HU: Collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; CSG: manuscript writing, final approval of manuscript; MV: Collection and/or assembly of data; MTP: Collection and/or assembly of data, final approval of manuscript; CB: Collection and/or assembly of data, final approval of manuscript; MSM: Collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; GB: Conception and design, manuscript writing, final approval of manuscript; JS: Conception and design, manuscript writing, final approval of manuscript; FC: Conception and design, manuscript writing, final approval of manuscript; JIN: Financial support, manuscript writing, final approval of manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All authors approved the publication of this manuscript.

Ethics approval and consent to participate
Not applicable.

Author details
1Department of Internal Medicine, Stem Cell Program, University of California Davis, Davis, USA. 2Department of Oncology-Pathology, Karolinska Institutet, Cancer Proteomics, Davis, USA. 2College of Medicine, Central Michigan University, Mt Pleasant, USA. 3West Coast Metabolomics Center, University of California, Davis, Davis, USA. 4Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia. 5Department of Molecular and Cellular Biology, University of California Davis, Davis, USA. 6Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 7Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. 8Department of Surgery, University of Washington, Seattle, USA. 9Department of Surgery, Center for Lung Biology, University of Washington, Seattle, USA. 10Institute for Regenerative Cures, University of California Davis Medical Center, 2921 Stockton Blvd, Room 1300, Sacramento, CA 95817, USA.

Received: 14 July 2016 Accepted: 12 September 2016

Published online: 01 November 2016

References
1. Thrift AG, Cadilhac DA, Thayabaranathan T, et al. Global stroke statistics. Int J Stroke. 2014;9:6–18.
2. Silver B, Lu M, Morris DC, et al. Blood pressure declines and less favorable outcomes in the NINDS tPA stroke study. J Neurol Sci. 2008;271:61–7.
3. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics–2016 Update: A Report From the American Heart Association. Circulation. 2016;133:e38–e360.
4. Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006;63:1057–62.
5. Keldahl ML, Eskandari MK. Timing of carotid surgery after acute stroke: Expert Rev Cardiovasc Ther. 2010;8:399–403.
6. Vu Q, Xie K, Eckert M, et al. Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology. 2014;82:1277–85.
7. Chamorro A, Meinse A, Planas AM, et al. The immunology of acute stroke. Nat Rev Neurol. 2012;8:401–10.
8. Rosova I, Dao M, Capoccia B, et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells. 2008;26:2173–82.
9. Fierro FA, Kalomoiris S, Sonderrgaard CS, et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells. 2011;29:11727–37.
10. Meyenroth T, Olson S, Pontow S, et al. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev. 2010;62:1167–74.
11. Uccelli A, Moretta L, Pistoa V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36.
12. Bronckaers A, Hilkens P, Martens W, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacol Ther. 2014;143:181–96.
13. Kwon HM, Hur SM, Park KY, et al. Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis. Vascul Pharmacol. 2014;63:19–28.
14. Hu J, Zhang L, Wang N, et al. Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int. 2013;84:521–31.
15. Zhang Y, Chopp M, Meng Y, et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosur. 2015;122:856–67.
16. Chen TS, Aslan F, Yin Y, et al. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J Transl Med. 2011;9:47.
17. Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845–54.
18. Tadokoro H, Iumezu T, Ohyashiki K, et al. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013;288:34343–51.
19. Katsuda T, Tsuchiya R, Kosaia N, et al. Human adipose tissue-derived mesenchymal stem cells secrete functional nephrilysin-bound exosomes. Sci Rep. 2013;3:1197.

20. Shabbir A, Cox A, Rodriguez-Menocal L, et al. Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro. Stem Cells Dev. 2015;24:1635–47.

21. Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10:301–12.

22. Zhang B, Yin Y, Lai RC, et al. Mesenchymal stem cell-secreted immunomodulatory active exosomes. Stem Cells Dev. 2014;23:1233–44.

23. Kordelas L, Rebmann V, Ludwig AK, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970–3.

24. Xin H, Li Y, Cui Y, et al. Systemic administration of exosomes released from mesenchymal stem cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab. 2013;33:1711–5.

25. Tomasi S, Longaretti L, Rota C, et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2013;22:772–80.

26. Lin SS, Zhu B, Guo ZK, et al. Bone marrow mesenchymal stem cell-derived microvesicles protect rat pheochromocytoma PC12 cells from glutamate-induced injury via a PI3K/Akt dependent pathway. Neurochem Res. 2014;39:322–31.

27. Bruno S, Grange C, Dereguibis MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20:1053–67.

28. Zhang HC, Liu XB, Huang S, et al. Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev. 2012;21:3289–97.

29. Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel). 2013;6:599–80.

30. Anderson JD, Johansson HJ, Graham CS, et al. Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via NFκB Signaling. Stem Cells. 2013;31:2737–46.

31. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stem cell therapy in patients with chronic ischemic stroke and the innate immune system. Nat Rev Immunol. 2012;12:3283–96.

32. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2011;29:887–90.

33. Chen JR, Cheng GY, Sheu CC, et al. Transplanted bone marrow stromal cells regulate the M1/M2 balance in mouse bone marrow-derived macrophages. J Immunol. 2014;192:252–60.

34. Cho DI, Kim MR, Jeong HY, et al. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp Mol Med. 2014;46:e70.

35. Koton S, Schneider AL, Rosamond WD, et al. Trends in stroke incidence and mortality in US communities, 1987 to 2011. JAMA. 2014;312:259–65.

36. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32:252–5.

37. Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel). 2013;6:599–80.

38. Anderson JD, Johansson HJ, Graham CS, et al. Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via NFκB Signaling. Stem Cells. 2013;31:2737–46.

39. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stem cell therapy in patients with chronic ischemic stroke and the innate immune system. Nat Rev Immunol. 2012;12:3283–96.

40. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2011;29:887–90.

41. Chen JR, Cheng GY, Sheu CC, et al. Transplanted bone marrow stromal cells regulate the M1/M2 balance in mouse bone marrow-derived macrophages. J Immunol. 2014;192:252–60.

42. Cho DI, Kim MR, Jeong HY, et al. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp Mol Med. 2014;46:e70.

43. Koton S, Schneider AL, Rosamond WD, et al. Trends in stroke incidence and mortality in US communities, 1987 to 2011. JAMA. 2014;312:259–65.

44. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2011;29:887–90.

45. Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel). 2013;6:599–80.

46. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2011;29:887–90.

47. Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel). 2013;6:599–80.

48. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2011;29:887–90.

49. Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel). 2013;6:599–80.

50. Marcus ME, Leonard JN. FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel). 2013;6:599–80.

51. Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.

52. Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.

53. Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.

54. Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.

55. Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.

56. Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.

57. Wei L, Fraser JL, Lu ZY, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.

58. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. J Cereb Blood Flow Metab. 2010;30:140–50.

59. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. J Cereb Blood Flow Metab. 2010;30:140–50.

60. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. J Cereb Blood Flow Metab. 2010;30:140–50.

61. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. J Cereb Blood Flow Metab. 2010;30:140–50.

62. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. J Cereb Blood Flow Metab. 2010;30:140–50.

63. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. J Cereb Blood Flow Metab. 2010;30:140–50.

64. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. J Cereb Blood Flow Metab. 2010;30:140–50.
65. Savitz SI, Misra V, Kasam M, Juneja H, Cox Jr CS, Alderman S, Alisku I, Kar S, Gee A, Grotta JC. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011;70(1):59–69. doi:10.1002/ana.22458.

66. Hess DC, Sila CA, Furlan AJ, Wechsler LR, Switzer JA, Mays RW. A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke. 2014;9(3):381–6. doi:10.1111/ijs.12065. Epub 2013 May 22.

67. Stroemer P, Patel S, Hope A, Oliveira C, Pollock K, Sinden J. The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion. Neurorehabil Neural Repair. 2009;23:895–909.

68. De La Pena I, Sanberg PR, Acosta S, Lin SZ, Borlongan CV. G-CSF as an adjunctive therapy with umbilical cord blood cell transplantation for traumatic brain injury. Cell Transplant. 2015;24:447–57.

69. Hara K, Yasuhara T, Maki M, Matsuaka N, Masuda T, Yu SJ, et al. Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke. Prog Neurobiol. 2008;85:318–34.

70. Kaneko Y, Hayashi T, Yu S, Tajiri N, Bae EC, Solomita MA, et al. Human amniotic epithelial cells express melatonin receptor MT1, but not melatonin receptor MT2: a new perspective to neuroprotection. J Pineal Res. 2011;50:272–80.

71. Liu SP, Fu RH, Wu DC, Hsu CY, Chang CH, Lee W, et al. Mouse-induced pluripotent stem cells generated under hypoxic conditions in the absence of viral infection and oncogenic factors and used for ischemic stroke therapy. Stem Cells Dev. 2014;23:421–33.

72. Li Z, McKercher SR, Cui J, Nie Z, Soussou W, Roberts AJ, et al. Myocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cells. J Neurosci. 2008;28:6557–68.

73. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol. 2011;95:213–28.

74. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, et al. Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. Stroke. 2016;47:1817–24.

75. Prasad K, Sharma A, Garg M, Mohanty S, Bhatnagar S, Johri S, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke. 2014;45:3618–24.

76. Borlongan CV. Bone marrow stem cell mobilization in stroke: a ‘bonehead’ may be good after all! Leukemia. 2011;25:1674–86.

77. Borlongan CV, Lind JG, Dillon-Carter O, Yu G, Hadman M, Cheng C, et al. Intracerebral xenografts of mouse bone marrow cells in adult rats facilitate restoration of cerebral blood flow and blood-brain barrier. Brain Res. 2004;1009:26–33.

78. Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV. Intravenous Bone Marrow Stem Cell Grafts Preferentially Migrate to Spleen and Abrogate Chronic Inflammation in Stroke. Stroke. 2015;46:2616–27.

79. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57:874–82.

80. Savitz SI, Misra V, Kasam M, Juneja H, Cox Jr CS, Alderman S, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011;70:59–69.

81. Banerjee S, Bentley P, Hamady M, Marley S, Davis J, Shlebak A, et al. Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke. Stem Cells. 2014;32:322–30.

82. Diamandis T, Borlongan CV. One, two, three steps toward cell therapy for stroke. Stroke. 2015;46:58–91.

83. Prockop DJ, Prockop SE, Bentonello I. Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology. Stem Cells. 2014;32:3055–61.

84. Beege JL, Lakatos K, Kalomoiris S, et al. Hypoxic Preconditioning of Mesenchymal Stromal Cells Induces Metabolic Changes, Enhances Survival and Promotes Cell Retention in Vivo. Stem Cells. 2015;14:919-24.